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A simple spectroﬂuorometric method has been developed, adapted, and validated for the quantitative estimation of drugs
containing α-methylene sulfone/sulfonamide functional groups using N1-methylnicotinamide chloride (NMNCl) as ﬂuorogenic
agent. The proposed methodhasbeen applied successfully to the determination of methyl sulfonylmethane (MSM)(1),tinidazole
(2),r o f e c o x i b(3), and nimesulide (4) in pure forms, laboratory-prepared mixtures, pharmaceutical dosage forms, spiked human
plasma samples, and in volunteer’s blood. The method showed linearity over concentration ranging from 1 to 150μg/mL, 10 to
1000ng/mL, 1 to 1800ng/mL, and 30 to 2100ng/mL for standard solutions of 1, 2, 3,a n d4, respectively, and over concentration
ranging from 5 to 150μg/mL, 10 to 1000ng/mL, 10 to 1700ng/mL, and 30 to 2350ng/mL in spiked human plasma samples of
1, 2, 3,a n d4, respectively. The method showed good accuracy, speciﬁcity, and precision in both laboratory-prepared mixtures
and in spiked human plasma samples. The proposed method is simple, does not need sophisticated instruments, and is suitable
for quality control application, bioavailability, and bioequivalency studies. Besides, its detection limits are comparable to other
sophisticated chromatographic methods.
1.Introduction
Encouraged by the successful application of the NMNCl
methodology to the determination of a similar α-methylene
carbonyl functional group containing drugs, namely, war-
farin [1],pentoxifylline, propafenonehydrochlorideandace-
butolol hydrochloride [2], the almost isosteric α-methylene
sulfoxide group, such as proton pump inhibitors (PPIs) and
the cyclic α-methylene carbonyl group, such as ketamine
hydrochloride, griseofulvin, and levonorgestrel (unpub-
lished results), we decided to investigate the possibility of
extending the application of such methodology to drugs
containing the isosteric α-methylene sulfone/sulfonamide
functional groups, namely, methyl sulfonyl methane (MSM)
(1), tinidazole (2),r o f e c o x i b(3), and nimesulide (4).
Methyl sulfonyl methane (MSM) (1) is a relatively new
dietary supplement form of sulfur that is found in our
living tissues. MSM supports healthy connective tissues like
tendons, ligaments, and muscle. Thus, it is important in
conditions such as arthritis, muscle pains, and bursitis.
MSM should be considered an integral part of any health
care practice because of its physiological action, indirect
importance, and current/future uses [3–5].
In this report, MSM was used as a model compound
and was found to react successfully with NMNCl quanti-
tatively yielding a ﬂuorophore. Because there are marketed
dosage forms containing MSM, it was decided to apply the
developed method for its analysis in its marketed dietary
supplement dosage forms in view of the rather elaborate and
costly methodologies reported for its analysis in the available
literature. The reported methods include Fourier-transform
infrared (FT-IR) spectrometry [6], Raman spectroscopy
[7], CIMS [8], GC [9], GC with ﬂame ionization detector
[10], GC with ﬂame photometric detection [11], capillary2 International Journal of Analytical Chemistry
GC [12], GC-MS for estimating volatile sulfur compounds
[13, 14], solid-phase microextraction-GC-MS [15], dynamic
headspace-GC-MS [16], reversed phase HPLC followed by
headspace GC-MS [17], and direct thermal desorption prior
to GC-MS application [18]. Tinidazole (2)i sas y n t h e t i c
antiprotozoal agent. Survey of the available literature reveals
several methods for the analysis of 2 active pharmaceutical
ingredient (API) and pharmaceutical formulations in the
presence of possible impurities and related substances [19,
20].Thesemethodsincludeﬂuorometryinvolvingthereduc-
tion of its nitro group and subsequent measurement of its
emission intensity at 420nm [21], UV [22], electrochemical
method [23], HPTLC [24, 25], LC/MS/MS [26], HPLC [27],
and GLC [28]. Further, 2 was analyzed in biological ﬂuids
containing its major metabolite using HPLC-MS [29].
Rofecoxib (3) is a nonsteroidal anti-inﬂammatory drug
(NSAID) introduced in 1998 with lots of fanfare claiming
it a selective COX-2 inhibitor with minimal side eﬀects,
and 3 was withdrawn in September, 2004 because of safety
concerns regarding its untoward cardiovascular side eﬀects
leading to several deaths [30, 31].
Diﬀerent methods are reported for the determination of
3 in the presence ofitsdegradation productsand metabolites
[32]. These methods include chemometric methods [32],
derivative UV [33, 34], HPTLC [35], HPLC after UV
photocyclization [36], and LC-MS [37].
Nimesulide (4) is a sulfonanilide analogue clinically used
anti-inﬂammatory agent; it is not related to conventional
NSAIDs, which usually present a carboxyl or hydroxyl func-
tional group [38]. Several methods were described for the
determination of 4 i nt h ep r e s e n c eo fi t sc o m p e n d i a - r e l a t e d
substances [39] as well as in the presence of its metabolites
[40]. These methods include spectrophotometric ones as
near-infrared [41], UV techniques [42], ﬂuorometry using
egg phosphatidylcholine liposomes [43], and colorimetric
methods [44]. Electrochemical methods involve ﬂow amper-
ometry [45] and adsorptive stripping voltammetry [46].
Separation methods involve HPLC [47, 48]a n dH P L C -
MS/MS [49].
Nakamura and Tamura described the application of the
reaction of N1-methylnicotinamide chloride (NMNCl) to
the analysis of various compounds containing α-methylene
carbonyl groups [50]. Nakamura and Tamura also made
qualitative tests on the reaction mechanism and established
thecyclizedα-adductﬂuorophore[50].Thisreactionwasnot
tested before forcompounds containing α-methylene groups
adjacent to other functional groups.
All previous publications based on the ﬂuorophore
produced by reaction with NMNCl described the utility of
this reagent to react with drugs containing active methylene
α to carbonyl functional groups. This paper formulates
our continuous eﬀort to extend the utility of NMNCl to
determine diﬀerent classes of drugs containing active methy-
lene α to various groups such as cyclic ketone, (ketamine,
griseofulvin, and levonorgestrel) sulfoxide (PPIs), and sul-
fone/sulfonamide (1–4) and even to groups that would
produce active methylene upon hydration, for example,
methyne group, such as levonorgestrel and ethinyl estradiol
(unpublished results).
Thispaperdescribestheapplicationandvalidation ofthe
reactionofNMNClwithsomedrugscontainingα-methylene
sulfone groups.
2.Resultsand Discussion
When 1, 2, 3,a n d4 (for chemical structures and plausible
pathway of the reaction, cf. Figure 1) were allowed to react
with NMNCl under the optimal conditions speciﬁed for
each,strongﬂuorescentproductswereobtained.Theoptimal
wavelengths of excitation and emission of the reaction
product were determined using synchronous wavelength
search and listed in Table 1.
Diﬀerent variables aﬀecting the reaction between the
chosen drugs and NMNCl, including sodium hydroxide
concentration and volume, volume and concentration of the
added NMNCl, and pH values, were studied to optimize the
reaction conditions to give maximum ﬂuorescence intensity
(Figures 2, 3,a n d4).
Under the optimum conditions for the reaction of
NMNCl with the chosen drug, linear relationships between
the ﬂuorescence intensity and the drug concentrations
were obtained in the following ranges: 1–150μg/mL, 10–
1000ng/mL, 1–1800ng/mL, and 30–2100ng/mL for stan-
dard solutions of 1, 2, 3,a n d4, respectively, and over
concentration ranges of 5–150μg/mL, 10–1000ng/mL, 10–
1700ng/mL, and 30–2350ng/mL for spiked human plasma
samples of 1, 2, 3,a n d4, respectively.
These results have revealed a good and dynamic linearity
ranges of the proposed method with diﬀerent drugs. The
good linearity of these relations was indicated by the
corresponding regression equations shown in Tables 2 and
3 for standard solutions and spiked human plasma samples,
respectively.
2.1. Detection Limit (DL). Detection limits were practically
determined according to the ICH topic Q2B (R1) [51]a n d
found to be 0.5μg/mL, 3ng/mL, 0.33ng/mL, and 10ng/mL,
for standard solutions and 0.7μg/mL, 5ng/mL, 0.6ng/mL,
and 18ng/mL, for plasma samples of 1, 2, 3,a n d4,
respectively.
2.2. Quantitation Limit (QL). Quantitationlimits were prac-
tically determined according to the ICH topic Q2B (R1)
[51]a n df o u n dt ob e1 μg/mL, 10ng/mL, 1ng/mL, and
30ng/mL, for standard solutions and 5μg/mL, 10ng/mL,
10ng/mL, and 30ng/mL, for plasma samples of 1, 2, 3,a n d
4, respectively.
2.3. Accuracy. The accuracy of the proposed method was
studied according to the ICH topic Q2B (R1) [51], by
preparing spiked human plasma samples containing various
concentrations, lying within the linearity range of each drug,
and analyzing them using the proposed method. The results,
expressed as % recovery ± S.D., are shown in Table 4 for
spiked human plasma samples.
2.4. Precision. The precision of the method was judged
by performing intraday and interday triplicate analyses of
diﬀerent concentrations covering the linearity range of eachInternational Journal of Analytical Chemistry 3
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Figure 1: Chemical structures of the analytes and plausible pathway for the reaction of NMNCl with α-methylene sulfone/sulfonamide
functional groups of 1–4.
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Figure 2: Eﬀect of NaOH concentration and volume on ﬂuorescence intensity of the reaction product of 1–4 with NMNCl. The variation
of NaOH concentration is made at constant volume and that of NaOH volume at constant concentration.
drug in spiked human plasma samples. The results are
reported as S.D. and coeﬃcient of variation (C.V.) in Table 5
for spiked human plasma samples.
2.5. Speciﬁcity. To study the speciﬁcity of the proposed
method, three synthetic mixtures of 1, 2,a n d3 and two
synthetic mixturesof 4 were prepared to contain thepossible
interfering substances used during pharmaceutical formu-
lations. These mixtures were analyzed using the proposed
method and the results, were expressed as % recovery ± S.D.,
and were as follows: 99.8% ± 3.0f o r1, 100.3% ± 2.8f o r2,
99.6% ± 3.5f o r3, and 100.7%± 1.7f o r4.4 International Journal of Analytical Chemistry
Table 1: Optimum conditions for the ﬂuorometric procedure.
Drug pH∗ NaOH
conc. (M)
NaOH
volume (mL)
NMNCl
conc. (mM)
NMNCl
volume (mL)
Cooling
time (min)
Heating
time (min) λex (nm) λem (nm)
1 3.0 6.0 1.1 1.0 0.9 9 6 350 395
2 3.2 5.0 1.0 2 × 10−1 1.0 10 3 336 391
3 2.5 7.0 0.9 4 × 10−1 1.2 8 5 354 440
4 1.5 8.0 1.0 5 × 10−1 0.9 7 3 325 375
∗The reaction pH.
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Figure 3: Eﬀect of NMNCl concentration and volume on ﬂuorescence intensity of the reaction product of 1–4 with NMNCl. The variation
of NMNCl concentration is made at constant volume and that of NMNCl volume at constant concentration.
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Figure 4: Eﬀect of pH on ﬂuorescence intensity of the reaction and
reaction product of 1–4 with NMNCl.
2.6. Assay of Pharmaceutical Preparations. All the pharma-
ceutical preparations available in the local market for each
drug were analyzed using the proposed method. The results,
expressed as % recovery ± S.D., are illustrated in Table 6.
2.7. Determination of 2 and 4 in Volunteer’s Blood. The
success in the application of the highly sensitive proposed
procedure for the determination of 2 and 4,i ns p i k e d
human plasma samples with good accuracy and precision,
encouraged the investigator to study its application for
monitoring the drug level in the blood of a volunteer
receiving 2 or 4 therapy. The level of 2 and 4 was monitored
in the blood of volunteers, and their concentrations were
found to be 48μg/mL and 35μg/mL, respectively, that lie
in the therapeutic levels of 2 (47.7 ± 7.5 μg/mL) and 4
(38 ± 10.6μg/mL).
3.Conclusion
The proposed method makes use of the high sensitivity
and speciﬁcity of the ﬂuorometric analysis to reach low
limits of detection and quantitation for all the studied
drugs in standard solutions, synthetic mixtures, pharma-
ceutical preparations, spiked human plasma samples, and
patient’s or volunteer’s blood. The method is simple; it gives
results comparable to those obtained by other techniques
that require elaborate instrumentation and time-consuming
sample preparation procedure.
T h em e t h o ds h o w e dg o o da c c u r a c ya n dp r e c i s i o ns u i t -
able for quality assurance and could be recommended forInternational Journal of Analytical Chemistry 5
Table 2: Regression analysis parameters for the determination of 1–4 in standard solutions using the proposed method.
Drug Linearity range Slope Intercept R2
Mean SE Mean SE
1 1–150μg/mL 4.9890 0.011 105.66 2.15 0.9997
2 10–1000ng/mL 0.8579 0.010 131.84 1.60 0.9998
3 1–1800ng/mL 0.5130 0.003 72.63 1.10 0.9995
4 30–2100 ng/mL 0.4155 0.005 113.20 2.78 0.9999
Average of triplicate analyses,13 data points.
Table 3: Regression analysis parameters for the determination of 1–4 in spiked human plasma samples using the proposed method.
Drug Linearity range
Slope Intercept
R2
Mean SE Mean SE
1 5–150μg/mL 4.8849 0.100 118.53 1.55 0.9991
2 10–1000ng/mL 0.7930 0.020 192.15 1.70 0.999
3 10–1700ng/mL 0.5342 0.010 49.64 1.57 0.9989
4 30–2350ng/mL 0.3110 0.003 254.48 1.35 0.9995
Average of triplicate analyses,13 data points.
Table 4: Recovery data of 1–4 in spiked human plasma samples using the proposed method.
Drug Claimed drug concentration ∗Recovered concentration % Recovery Mean % recovery ± S.D. C.V.
1 (μg/mL)
5 5.02 100.4%
100.3± 2.0 2.0%
20 20.20 101.0%
60 59.00 98.3%
80 78.00 97.5%
100 102.30 102.3%
150 153.00 102.0%
2 (ng/mL)
10 9.8 98.00%
99.98 ± 1.9 1.9%
30 30.5 101.60%
50 51.0 102.00%
100 102.0 102.00%
300 295.0 98.30%
500 490.0 98.00%
800 810.0 101.20%
1000 987.0 98.70%
3 (ng/mL)
10 10.2 102.0%
100.4 ± 1.4 1.4%
100 102.0 102.0%
300 297.0 99.0%
800 807.0 100.9%
1000 991.0 99.1%
1500 1515.0 101.0%
1700 1685.0 99.1%
4 (ng/mL)
30 29.6 98.7%
99.96 ± 1.5 1.5%
100 98.0 98.0%
500 509.0 101.8%
1000 1015.0 101.0%
1200 1181.0 98.4%
1500 152.5 101.6%
1800 1809.0 100.5%
2100 2345.0 99.7%
∗Average of triplicate analyses.6 International Journal of Analytical Chemistry
Table 5: Intraday and interday precision of 1–4 determination in plasma samples using the proposed method.
Drug Claimed conc. Intraday Interday
Found conc∗ S.D. C.V. Found conc∗ S.D. C.V.
1 (μg/mL)
5 5.03 0.02 0.4% 4.9 0.71 0.14%
20 20.1 0.07 0.4% 19.7 0.21 1.10%
60 61.3 0.90 1.5% 58.6 0.99 1.70%
80 78.0 0.14 1.7% 83.0 2.12 2.60%
100 104.0 2.80 2.8% 97.0 2.12 2.15%
150 154.0 2.80 1.9% 146.0 2.80 1.90%
2 (ng/mL)
10 9.7 0.21 2.2% 9.8 0.14 1.42%
30 29.3 0.50 1.7% 30.5 0.35 1.16%
50 51.5 1.10 2.1% 49.0 0.71 1.43%
100 102.0 1.40 1.4% 102.0 1.40 1.40%
300 296.0 2.80 1.0% 289.0 7.78 2.60%
500 512.0 8.40 1.7% 510.0 7.10 1.40%
800 795.0 3.50 0.4% 810.0 7.10 1.87%
1000 985.0 10.60 1.1% 985.0 10.60 1.10%
3 (ng/mL)
10 10.4 0.30 2.8% 10.3 0.21 2.08%
100 96.0 2.80 2.9% 96.0 2.82 2.90%
300 304.0 2.80 0.9% 305.0 3.50 1.20%
500 495.0 0.35 0.7% 506.0 4.24 0.84%
1000 1020.0 14.10 1.4% 1020.0 14.10 1.40%
1100 1125.0 17.70 1.6% 1125.0 17.70 1.60%
1500 1475.0 17.70 1.2% 1485.0 10.60 0.71%
1700 1720.0 14.10 0.8% 1720.0 14.10 0.83%
4 (ng/mL)
30 29.4 0.40 1.40% 30.3 0.21 0.70%
100 98.0 1.40 1.40% 104.0 2.83 2.80%
500 505.0 3.50 0.70% 491.0 6.36 1.28%
1000 1015.0 10.60 1.10% 980.0 14.10 1.40%
1200 1185.0 10.60 0.90% 1225.0 17.70 1.45%
1500 1524.0 16.90 1.10% 1529.0 20.50 1.35%
1800 1815.0 10.60 0.60% 1780.0 14.10 0.79%
2350 2340.0 7.10 0.30% 2360.0 7.10 0.30%
∗Average of triplicate analyses.
bioequivalency and bioavailability studies as well as for
validation of cleaning methodology prior to line clearance
during manufacture of said dosage forms.
The proposed method application could be extended to
cover all available pharmaceutical preparations for each of
the chosen drugs.
4.Experimental
4.1. Apparatus. Shimadzu RF 5301 PC spectroﬂuorometer.
4.2. Materials
4.2.1. AuthenticDrugs. 1, 2, 3,a n d4 working standards were
supplied by Eva Pharma for Pharmaceutical Industries and
Medical Appliances, Egypt, Medical Union Pharmaceuticals
(MUP), Egypt, October Pharma, Egypt, and Sigma Pharma-
ceutical Industries, Egypt, respectively.
Plasma samples were purchased from the Central Blood
Bank of Tanta University Hospital.
4.2.2. Other Chemicals. N1-Methylnicotinamide chloride
was obtained from Sigma Chemicals Co. Formic acid,
sodium hydroxide, methanol, and all other chemicals were
of analytical grade. Water used was doubly distilled.
4.2.3. Dosage Forms. MSM (1):M S M1gt a b l e t s( E v aP h a r -
ma).
Tinidazole (2): Fasigyn 500mg tablets (Pﬁzer) and Proto-
zol 500mg tablets (MUP).
Rofecoxib (3):Romacox25mgtablets(OctoberPharma).International Journal of Analytical Chemistry 7
Table 6: Results of the recovery experiments of 1–4 in diﬀerent pharmaceutical preparations.
Drug Pharmaceuticalpreparations % Recovery ±SD
∗
1 (MSM) 1000mg tablet 101 ± 2.0%
2 (Protozol) 500mg tablet 101 ± 1.6%
(Fasigyn) 500mg tablet 98 ± 2.5%
3 (Romacox) 25mg tablet 103 ± 0.7%
4
(Nimalox) 100mg tablet 102.2 ±3.0%
(Sulide) 100mg tablet 101.6 ±3.6%
(Sulide)5 0mgt ab l e t 9 9 .9 ±1.8%
(Sulidan) 100mg tablet 101.6 ±3.2%
∗Average of triplicate analyses.
Nimesulide (4): Sulide 50mg and 100mg tablets (Alkan
Pharma), Nimalox 100mg tablets (Sigma) and sulidan
100mg tablets (Modern Pharmaceutical Co. (MPC)).
4.3. Reagents and Standard Solutions
4.3.1. Stock Standard Solutions of Drugs. Stock standard
solutionswere prepared in distilled water for 1,m e t h a n o lf o r
3, and ethanol for 2 and 4 to contain 10mg/mL, 10mg/mL,
0.2mg/mL, and 0.25mg/mL for 1, 2, 3,a n d4, respectively.
4.3.2. Serial Standard Solutions of Drugs. Aliquots of the
stock solution were diluted quantitatively with the same
solvent to obtain serial standard solutions in concentration
ranging from 0.1 to 15mg/mL, 0.1 to 10μg/mL, 0.01 to
20μg/mL and 0.1to250μg/mL for1,2,3,and4,respectively.
4.4. Assay Solutions of Drugs in Synthetic Mixtures. Three
synthetic mixtures containing 1 along various excipients,
additives,andothernonactiveingredients commonlyusedin
pharmaceutical formulations were prepared. The ﬁrst mix-
ture contained 1000mg 1, 135mg starch, 60mg gelatin, and
8.0mg magnesium stearate. The second mixture contained
1000mg 1,7 5m gl a c t o s e ,3 0m gs t a r c h ,6 0m gg e l a t i n ,8 . 0m g
magnesium stearate, and 42mg talc. The third mixture
contained 100mg avicel instead of lactose and gelatin.
Three synthetic mixtures containing 2 were prepared.
The ﬁrst mixture contained 500mg 2, 200mg cellose, 72mg
starch, 8.0mg magnesium stearate, 8.0mg polyethylene
glycol and 1.0mg titanium dioxide. The second mixture
contained 500mg 2 and, 100mg lactose, 60mg starch, 60mg
gelatin, 8.0mg magnesium stearate and 72mg talc. The
third mixture contained 160mg avicel instead of lactose and
gelatin.
Three synthetic mixtures containing 3 were prepared.
The ﬁrst mixture contained 25mg 3, 100mg croscarmellose,
83.5mg lactose, and 8.0mg stearate. The second mixture
contained 25mg 3, 60mg citric acid, 80mg sodium citrate,
and 10% sorbitol solution. The third mixture contained
25mg 3, 235mg lactose, 60mg gelatin, 8.0mg magnesium
stearate, and 72mg talc.
Two synthetic mixtures containing 4 along with various
excipients and additives were prepared. The ﬁrst mixture
contained 100mg 4, 200mg lactose, 60mg starch, 60mg
gelatin, 8.0mg magnesium stearate, and 72mg talc. The
second mixture contained 260mg avicel instead of lactose
and gelatin.
Each synthetic mixture containing 1, 2, 3,o r4 was
extracted with 100mL of distilled water for 1,m e t h a n o lf o r
2,o re t h a n o lf o r3 and 4, ﬁltered, and the ﬁrst 10mL of the
ﬁltrate was rejected. Aliquotsof the ﬁltrate were diluted with
the same solvents to obtain serial dilutions in concentrations
ranging from 0.1 to 25mg/mL, 0.1 to 10μg/mL, 0.01 to
20μg/mL and 0.1 to 25μg/mL, for 1, 2, 3,a n d4, respectively.
4.5.AssaySolutionsofDrugsinTheir PharmaceuticalPrepara-
tions. Twenty tablets were ﬁnely powdered, a quantity of the
powder, equivalent to one tablet of 1–4, was transferred with
the aid of several portions of distilled water for 1,m e t h a n o l
for 3 or ethanol for2,4 to a 100mL volumetric ﬂask and the
volume was completed with the same solvent. The resulting
solution was ﬁltered and the ﬁrst 10mL of the ﬁltrate was
rejected. Aliquots of the ﬁltrate were diluted with the same
solventsto obtain100μg/mL, 6μg/mL, 5μg/mL and 6μg/mL
solutions, for 1,2,3 and 4, respectively.
4.6. Assay Solutions of Drugs in
Spiked Human Plasma Samples
4.6.1. Serial Standard Solutions of the Drugs. Serial stan-
dard solutions were prepared in distilled water (for 1), in
methanol (for 2), and in ethanol (for 3 and 4)i nc o n c e n -
trations ranging from 1 to 150mg/mL, 0.01 to 1mg/mL,
0.001 to 2.0mg/mL and 0.01 to 2.5mg/mL of 1, 2, 3,a n d
4, respectively.
4.6.2. Preparation of Spiked Human Plasma Samples. Two
hundred μL of each of the serial standard solutions of 1
were diluted with 1800μL human plasma and vortex mixed
to obtain concentrations ranging from 0.1 to 15mg/mL.
2, 3,a n d4 200μL of each drug serial standard solution
were evaporated; the residue was dissolved in 1800μL
human plasma and vortex mixed, 200μLd i s t i l l e dw a t e r
was added and vortex mixed to obtain 0.001–0.1mg/mL,
0.0001–0.2mg/mL, and 0.001–0.25mg/mL of 2, 3,a n d4,
respectively.8 International Journal of Analytical Chemistry
4.7. Preparation of Assay Solutions of Drugs in Plasma
Samples. Two hundred μL of spiked human plasma samples
(cf. preparation of spiked human plasma samples) were
mixedwith1800μLmethanolandcentrifugedfor15minutes
to separate the precipitated protein. The clear supernatant
was ﬁltered through Millipore ﬁlter (0.45μm) to obtain
solutions in concentration range of 0.01–1.5mg/mL, 0.1–
10μg/mL, 0.01–20μg/mL, and 0.1–25μg/mL for 1, 2, 3,a n d
4, respectively.
4.8. Determination of 2 and 4 in Volunteer’s Blood. Blood
sample was withdrawn in a test tube to which heparin was
previously added and dried. The sample was centrifuged to
separate plasma and then treated as previously mentioned
under preparation of assay solutions of 2 and 4 in plasma
samples(cf.preparationofassay solutionsofdrugsinplasma
samples).
4.9.N1-Methylnicotinamide Chloride Reagent (NMNCl). Ten
mM solution NMNCl reagent was prepared by dissolving
17.262g NMNCl in one liter of 10−4 N HCl. Aliquots of
this solution were diluted with distilled water to obtain
1.0mM,2.0 ×10−1 mM,4.0 ×10−1 mM,and5.0 ×10−1 mM
solutions.
4.10. General Fluorometric Procedure. One milliliter of each
drug standard solutions, assay solutions of synthetic mix-
tures, assay solutions of pharmaceutical preparations, assay
solutions of plasma samples, or the assay solution of the
volunteer’s plasma was transferred to 10.0mL screw-capped
test tube. Solutions of sodium hydroxide and NMNCl were
added. The mixture was cooled (in ice) for the indicated
time, then the pH was adjusted using formic acid and
heated for the indicated time and then was cooled in ice
for 5 minutes (optimum NaOH concentration and volume,
volume and concentration of added NMNCl, reaction pH
values) and cooling and heating times are indicated in
Table 1. The mixture was transferred to 10.0mL volumetric
ﬂask,andtheresultingsolutionwascompletedusingdistilled
water. In case of 4, the pH of the reaction product
was adjusted to 10.0 before completing to volume with
distilledwater. The intensity oftheresulting ﬂuorescencewas
measured at the optimal wavelengths indicated in Table 1.
The ﬂuorometric measurements were performed against
reagent blank experiments. Concentrations of the drugs
were calculated from the corresponding calibration graphs
prepared simultaneously.
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